Terms of Use. Terms of Use.

Slides:

Advertisements

Similar presentations

Medical Rx (cath) Time AdmissionCathDischarge No Cath Cath PCI Surgery Medical Rx (no cath) Medical Rx No disease (82 % of total) (18 % of total) (52%

Advertisements

Leadership. Knowledge. Community. Guideline Pearls Canadian Cardiovascular Society Antiplatelet Guidelines.

Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.

Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.

Update on the Medical Management of Acute Coronary Syndrome.

Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.

ACUTE CORONARY SYNDROMES:

PRODIGY Objective Study Design Primary Composite Endpoint

? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.

M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

Canadian Cardiovascular Society Antiplatelet Guidelines

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Copyright © 2008 American Medical Association. All rights reserved.

William Wijns MD PhD Thomas Cuisset MD

European and US Guidelines

(p < for group 1 or 2 vs. group 3)

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Anticoagulants in Interventional Cardiology:

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Achieving Long-Term Protection Post-MI

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,

The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Alan D. Bell, MD, CCFP, André Roussin, MD, FRCPC,

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

What Has Been Tried and What Is True?

How and When to Decide on Revascularization in Stable Ischemic Heart Disease.

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

Peter K. Smith, MD The Annals of Thoracic Surgery

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

Category: PCI Research

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

MACE: Death, MI or TLR at 5 years

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

Glenn N. Levine et al. JACC 2011;58:e44-e122

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Forest plot illustrating risk ratio of stent thrombosis

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Antithrombotic Therapy in AF Patients Undergoing PCI

Presentation transcript:

Terms of Use

Timing of Elective Surgery in Patients With Coronary Stents

Stent Generations

Recommendations for Duration of DAPT in Patients With Stable Ischemic Heart Disease Treated With PCI

Recommendations for Duration of DAPT in Patients With Stable Ischemic Heart Disease Treated With PCI

Recommendations for Duration of DAPT in Patients With Acute Coronary Syndrome Treated With PCI

Recommendations for Elective Noncardiac Surgery in Patients Who Have Been Treated With PCI and DAPT

Considerations When Balancing Risks of Surgery Delay vs Considerations When Balancing Risks of Surgery Delay vs. Risk of Discontinuation of DAPT Risk Factors for Stent Thrombosis

Our Response